205 related articles for article (PubMed ID: 12359989)
21. Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study.
Malmqvist K; Kahan T; Edner M; Bergfeldt L
J Hum Hypertens; 2007 Dec; 21(12):956-65. PubMed ID: 17637792
[TBL] [Abstract][Full Text] [Related]
22. The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SILVHIA).
Liljedahl S; Kahan T; Lind L; Arnlöv J
Echocardiography; 2009 Aug; 26(7):753-8. PubMed ID: 19486119
[TBL] [Abstract][Full Text] [Related]
23. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
Schiffrin EL; Park JB; Pu Q
J Hypertens; 2002 Jan; 20(1):71-8. PubMed ID: 11791028
[TBL] [Abstract][Full Text] [Related]
24. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.
Schneider MP; Klingbeil AU; Delles C; Ludwig M; Kolloch RE; Krekler M; Stumpe KO; Schmieder RE
Hypertension; 2004 Jul; 44(1):61-6. PubMed ID: 15184349
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension.
Stumpe KO; Haworth D; Hoglund C; Kerwin L; Martin A; Simon T; Masson C; Kassler-Taub K; Osbakken M
Blood Press; 1998 Jan; 7(1):31-7. PubMed ID: 9551875
[TBL] [Abstract][Full Text] [Related]
26. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
27. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.
von zur Mühlen B; Kahan T; Hägg A; Millgård J; Lind L
J Hypertens; 2001 Oct; 19(10):1813-8. PubMed ID: 11593101
[TBL] [Abstract][Full Text] [Related]
28. Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression.
Cohen A; Bregman B; Agabiti Rosei E; Williams B; Dubourg O; Clairefond P; Brudi P; Gosse P; Guéret P
J Hum Hypertens; 1998 Jul; 12(7):479-83. PubMed ID: 9702935
[TBL] [Abstract][Full Text] [Related]
29. Treatment of diastolic dysfunction in hypertensive left ventricular hypertrophy.
Bella JN
Am J Hypertens; 2006 Sep; 19(9):937-8. PubMed ID: 16942936
[No Abstract] [Full Text] [Related]
30. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol.
Makris TK; Stavroulakis GA; Krespi PG; Hatzizacharias AN; Triposkiadis FK; Tsoukala CG; Votteas VV; Kyriakidis MK
Am J Hypertens; 2000 Jul; 13(7):783-8. PubMed ID: 10933570
[TBL] [Abstract][Full Text] [Related]
31. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
[TBL] [Abstract][Full Text] [Related]
32. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.
Pool JL; Guthrie RM; Littlejohn TW; Raskin P; Shephard AM; Weber MA; Weir MR; Wilson TW; Wright J; Kassler-Taub KB; Reeves RA
Am J Hypertens; 1998 Apr; 11(4 Pt 1):462-70. PubMed ID: 9607385
[TBL] [Abstract][Full Text] [Related]
33. Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment.
Liljedahl U; Lind L; Kurland L; Berglund L; Kahan T; Syvänen AC
BMC Cardiovasc Disord; 2004 Sep; 4(1):16. PubMed ID: 15453913
[TBL] [Abstract][Full Text] [Related]
34. Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray.
Wen SY; Wang H; Sun OJ; Wang SQ
World J Gastroenterol; 2003 Jun; 9(6):1342-6. PubMed ID: 12800253
[TBL] [Abstract][Full Text] [Related]
35. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
Strutz F; Bramlage P; Paar WD
Curr Med Res Opin; 2005 Sep; 21(9):1433-40. PubMed ID: 16197662
[TBL] [Abstract][Full Text] [Related]
36. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
Pechère-Bertschi A; Nussberger J; Decosterd L; Armagnac C; Sissmann J; Bouroudian M; Brunner HR; Burnier M
J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932
[TBL] [Abstract][Full Text] [Related]
37. Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers.
Schiffrin EL
Can J Cardiol; 2002 May; 18 Suppl A():15A-18A. PubMed ID: 12045789
[TBL] [Abstract][Full Text] [Related]
38. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
[TBL] [Abstract][Full Text] [Related]
39. CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population.
Hong X; Zhang S; Mao G; Jiang S; Zhang Y; Yu Y; Tang G; Xing H; Xu X
Eur J Clin Pharmacol; 2005 Oct; 61(9):627-34. PubMed ID: 16094537
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension.
Dahlöf B; Keller SE; Makris L; Goldberg AI; Sweet CS; Lim NY
Am J Hypertens; 1995 Jun; 8(6):578-83. PubMed ID: 7662242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
